I am a
Home I AM A Search Login

Papers of the Week

2021 Feb 22


Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in Obstructive Sleep Apnea: An Analysis of Subgroups Adherent or Nonadherent to Obstructive Sleep Apnea Treatment.



Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, is approved in the USA to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) (37.5-150 mg/d).